Improvement in bladder function in children with functional constipation after a bowel management program

Maria E. Knaus1,2 · Hira Ahmad1 · Tran Bourgeois2 · Daniel G. Dajusta3 · Richard J. Wood1 · Molly E. Fuchs3

Accepted: 12 June 2022 / Published online: 5 August 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract
Purpose We sought to determine if children with functional constipation (FC) would have an improvement in bladder function with treatment of constipation with a bowel management program (BMP).

Methods A single-institution review was performed in children aged 3–18 with FC who underwent a BMP from 2014 to 2020. Clinical characteristics, bowel management details, and the Vancouver Symptom Score for Dysfunctional Elimination Syndrome (VSS), Baylor Continence Scale (BCS), and Cleveland Clinic Constipation Score (CCCS) were collected. Data were analyzed using linear mixed effect modeling with random intercept.

Results 241 patients were included with a median age of 9 years. Most were White 81 and 47% were female. Univariate tests showed improvement in VSS (−3.6, \(P<0.0001\)), BCS (−11.96, \(P<0.0001\)), and CCCS (−1.9, \(P<0.0001\)) among patients having undergone one BMP. Improvement was noted in VSS and CCCS among those with more than one BMP (VSS: −1.66, \(P=0.023\); CCCS: −2.69, \(P<0.0001\)). Multivariate tests indicated undergoing a BMP does result in significant improvement in VSS, BCS, and CCCS (\(P<0.0001\)).

Conclusions There is significant improvement in bladder function in children with FC who undergo a BMP. For patients with bowel and bladder dysfunction and FC, a BMP is a reasonable treatment strategy for lower urinary tract symptoms.

Keywords Bowel and bladder dysfunction · Dysfunctional elimination syndrome · Urinary dysfunction · Urotherapy

Abbreviations
ARM Anorectal malformation
BBD Bowel and bladder dysfunction
BCS Baylor continence scale
BMP Bowel management program
CCCS Cleveland clinic constipation score
DES Dysfunctional elimination syndrome
FC Functional constipation

PROM Patient-reported outcomes measure
VSS Vancouver symptom score for dysfunctional elimination syndrome

Introduction
Bowel and bladder dysfunction (BBD), previously known as dysfunctional elimination syndrome (DES), is a common clinical entity that describes concomitant lower urinary tract symptoms and issues with constipation and/or fecal incontinence [1–3]. An increased fecal load in the rectum can cause mechanical compression of the bladder and affect the shared neural pathways of the bladder, bowel, and pelvic floor, resulting in decreased bladder capacity, urge incontinence, frequency, a decreased urge to evacuate, insufficient emptying, bladder spasms, and high post-void residual volumes [4, 5]. This may also result in vesicoureteral reflux and recurrent urinary tract infections with potential subsequent renal failure [4, 6].

The Vancouver Symptom Score for Dysfunctional Elimination Syndrome (VSS) is a patient-reported outcomes...
measure (PROM) that has been validated to diagnose BBD in pediatric patients [7, 8]. Urotherapy, which consists of hydration, timed voiding regimens, pelvic floor biofeedback, clean intermittent catheterization, and pharmacologic therapy, has been shown to significantly improve the VSS and quality of life in children and adolescents with BBD [9]. Several studies have also shown improvement in BBD after treatment of constipation [6, 10, 11]. A bowel management program (BMP) is a formal, tailored program that employs a variety of treatment strategies to improve severe pediatric constipation and fecal incontinence when standard medical management has failed [12–14]. Strategies employed during the bowel management week include dietary changes, oral laxatives and other medication, rectal enemas, and antegrade continence enemas. Progress is monitored throughout the BMP week using daily stooling diaries and abdominal X-rays and adjustments to each patient’s regimen are made as needed.

A recent study examining continence outcomes in patients with anorectal malformation was able to show that undergoing a BMP improved urinary symptoms in these patients with underlying anatomic abnormalities of the urologic system [15]. While not specific for improvement in BBD, the Baylor Continence Scale (BCS) and Cleveland Clinic Constipation Score (CCCS) are also PROMs that are used to assess changes in bowel and bladder symptoms after intervention, which the aforementioned study examined as well [16, 17]. It has not been established whether a BMP alone improves urinary symptoms in patients with functional constipation (FC) and BBD with no underlying anatomic abnormalities. The objective of this study was to determine whether a BMP can improve urinary symptoms in patients with FC and BBD by examining changes in the VSS and other PROMs before and after the program.

Methods

Participants

After local Institutional Board Review approval (STUDY00001799), a single-institution, retrospective cohort study was performed among patients with FC, aged 3–18 years, who underwent a formal BMP at these authors’ institution from April 2014 to August 2020. Study dates encompass the first year of our comprehensive multidisciplinary colorectal clinic up to present day. Functional constipation was defined using the Rome IV criteria [18]. Patients who did not have FC or did not complete a BMP at our center were excluded, as were those who met the Rome IV criteria for irritable bowel syndrome. All patients who underwent BMP underwent a prospective consent process and were contacted via email by nurse clinicians for follow-up questionnaire completion.

Study measures

Given the difficulty of objectively describing urinary symptoms such as enuresis, urgency, and frequency in this patient population, we sought to find a standardized method to evaluate urinary symptoms. The primary outcome of interest was the change in scores for the VSS, the BCS, and the CCCS before and after BMP [7, 16, 17]. The VSS is an instrument aimed at capturing DES or BBD. All 14 items use a 5-point Likert scale, with a score of greater than or equal to 11 indicating the presence of DES or BBD—improvement to a score of 10 or less is ideal. Of the VSS, only three questions pertain to bowel symptoms and the remaining questions pertain to urinary symptoms. The BCS has been validated in children with anorectal malformation and is used to assess social continence. All 23 items use a Likert scale with final scores ranging from 2 to 84; lower scores reflect better social continence. Lastly, the CCCS is often used as a measure for determining the extent and severity of constipation. Scores in this instrument range from 0 to 30, with higher scores indicating more severe constipation. These questionnaires are completed electronically via the Research Electronic Data Capture tool by parents prior to the BMP and at the completion of the BMP at 1-month and 3-month follow-up.

Bowel management program

The BMP at the authors’ institution consists of a week-long program that can either be completely in-person or partially/fully remote via telemedicine. The telemedicine option was introduced after the onset of the COVID-19 pandemic. Patients receive individually tailored bowel regimens that are adjusted throughout the week based on abdominal films, symptoms, and daily stooling charts to achieve social fecal and urinary continence. Examples of different regimens include combinations of oral laxatives and fiber, rectal enemas, and antegrade continence enemas via Malone appendicostomy or cecostomy.

Cohort information

Sociodemographic information was collected on all patients. Clinical characteristics collected on patients consisted of whether the child was potty-trained or catheterized, BMP date(s), BMP regimen (oral laxatives/medication, suppository, antegrade or rectal enema, combination), and PROMs before and after undergoing the BMP. Outcome scores were included in the analysis if the scores were collected at least 9 months prior to BMP during the intake process. Follow-up scores up to 1-year post-BMP were included in
analyses. Modeling was conducted on one cohort consisting of patients who underwent only one round of BMP. The second cohort analyzed consisted of those with multiple rounds of BMP of which only the most recent BMP program was assessed.

**Statistical analysis**

Continuous data were reported as medians and interquartile range while categorical data were reported as frequencies and proportions. Univariate tests were carried out using paired t tests to detect differences in scores. To account for possible differences between patients who underwent one BMP from those that underwent multiple BMPs, univariate tests were conducted separately on patients with one BMP from those that had multiple BMPs. Linear mixed effect regression modeling with a random intercept was conducted after checking that all assumptions were satisfied and correlation among variables explored. Model building was conducted via the backward selection process with variables removed if partial F P values were greater than or equal to 0.10. Individual groups with the highest count were selected as the reference group in most models. Final model selection was conducted after lowest Akaike information criterion and Bayesian information criterion were determined. Adjustments for multiple comparisons were done using Tukey's multiple comparison test. Findings were determined to be significant at P < 0.05. All statistical tests were conducted on SAS Enterprise version 8.1.

**Results**

A total of 241 patients met inclusion criteria (Table 1). Most patients were White (81%) and potty-trained (91%). Females comprised 47% of the cohort. The majority of patients did not have a behavioral disorder (66%) and over half had no spinal abnormalities (56%). The median age of patients at the time of the most recent BMP was 9 years (IQR: 7, 13). 72 percent of patients required only one BMP. The most common BMP regimen was oral laxatives/medication (61%) followed by enemas (30%).

Median time at which the follow-up VSS was recorded after the BMP was 92 days (IQR: 31, 153). Univariate tests indicate significant improvement in VSS (mean drop in score of 3.6, (95% CI 2.72, 4.48), P < 0.0001), BCS (mean drop in score of 11.96, (95% CI 9.41, 14.5), P < 0.0001), and CCCS (mean drop in score 1.9, (95% CI 1.06, 2.73), P < 0.0001) among patients having undergone one BMP (Table 2). Significant improvement in scores was also noted in the VSS and CCCS among those who underwent more than one BMP (mean drop in score 1.66, (95% CI: 0.23, 3.09), P = 0.023 for VSS; mean drop in score 2.69, (95% CI: − 0.91, 6.28), P < 0.0001 for CCCS). (Table 3). However, improvement in the BCS was observed but not found to be significant (mean drop in score 2.69, (95% CI − 0.91, 6.28), P=0.14). Multivariate tests indicate that even after adjusting for all covariates, undergoing a BMP does result in significant.

| Table 1 General cohort characteristics | Total (n=241) |
|----------------------------------------|-------------|
| Age at BMP, years (median, IQR)       | 9 (7.13)    |
| Gender (n=232)                         |             |
| Male                                   | 119 (49.38) |
| Female                                 | 113 (46.89) |
| Race (n=214)                           |             |
| White                                  | 196 (81.33) |
| Bi-racial or Multi-racial              | 7 (2.9)     |
| Other                                  | 6 (2.49)    |
| Black                                  | 5 (2.07)    |
| Ethnicity (n=67)                       |             |
| Hispanic                               | 4 (1.84)    |
| Catheterized (n=237)                   | 11 (4.56)   |
| Behavioral disorder (n=240)            |             |
| None                                   | 158 (65.65) |
| More than one                          | 36 (14.94)  |
| ADHD                                   | 27 (11.2)   |
| Autism                                 | 9 (3.73)    |
| Other                                   | 8 (3.32)    |
| OCD                                    | 1 (0.41)    |
| Developmental delay (n=240)            | 40 (16.6)   |
| Spinal status (n=240)                  |             |
| Normal                                 | 136 (56.43) |
| Unknown                                | 86 (35.68)  |
| More than one                          | 8 (3.32)    |
| Fatty filum                            | 4 (1.66)    |
| Tethered cord                          | 3 (1.24)    |
| Myelomeningocele/spina bifida          | 3 (1.24)    |
| Number of BMPs                         |             |
| One                                    | 173 (71.78) |
| Two                                    | 58 (24.07)  |
| Three                                   | 9 (3.73)    |
| Four                                    | 1 (0.41)    |
| BMP regimen (n=232)                    |             |
| Oral laxative/medication               | 146 (60.58) |
| Enema                                  | 72 (29.88)  |
| Oral laxative/medication & enema       | 11 (4.56)   |
| Oral laxative/medication & suppository | 2 (0.83)    |
| Enema & suppository                    | 1 (0.41)    |

Age at BMP is at most recent BMP encounter

IQR interquartile range, ADHD Attention-deficit/hyperactivity disorder, OCD obsessive–compulsive disorder, BMP bowel management program
improvement in the VSS, BCS, and CCCS ($P < 0.0001$) (Table 4). Patients who underwent multiple BMPs also showed improvement in their scores, though this improvement was only significant for BCS ($P = 0.0001$).

Marginal means estimates looking at changes in scores pre- and post-BMP by individual regimen indicate decreases in scores among regimens involving oral laxatives/medication or enemas (Table 5). Regimens involving oral laxatives/medication revealed significant decreases in all three scores ($P = 0.0001$ for VSS, $P = 0.0002$ for BCS, and $P < 0.0001$ for CCCS). Regimens using enemas resulted in larger mean differences in both the VSS and BCS (mean difference $-4.05$ (95% CI: $-6.51, -1.58$), $P < 0.0001$ for VSS; mean difference $-14.67$ (95% CI: $-20.43, -8.91$), $P < 0.0001$ for BCS).

### Discussion

This study shows that there is significant improvement in urinary symptoms in children with FC who undergo a BMP. This is evidenced by the significant improvement in VSS. For challenging patients with BBD and FC, a BMP is a reasonable treatment strategy to treat lower urinary tract symptoms.

The VSS is a 14-item questionnaire that assesses urinary continence and also the severity of symptoms associated with BBD and fecal incontinence [7]. A score of 11 or higher is indicative of nonneurogenic lower urinary tract dysfunction/dysfunctional elimination syndrome, with a sensitivity of 80% and specificity of 91%. The median pre-BMP VSS score in our cohort was 14, which would characterize the patients as having DES. After the BMP, the median VSS decreased to a median of 10, thereby showing enough improvement in patient symptoms to the degree that they no longer were considered dysfunctional eliminators. This was true in patients who performed only one BMP and those who underwent multiple BMP. Both of these groups ultimately scored a median of less than 11 which suggests that improvement and resolution of BBD is possible with BMP alone.

It has been shown previously in patients with anorectal malformation who have underwent a BMP that the VSS improves as fecal continence in the population improves [15]. Children with anorectal malformation have known associated urologic abnormalities and commonly have difficulty with urinary and bowel elimination. Additionally, children with these malformations often have multiple surgical procedures that may impact bowel and bladder function. In contrast, children with FC have normal urologic and colorectal anatomy and rarely, if ever, has surgery been performed. Our finding that BMP alone significantly improves VSS in these patients reinforces the well-accepted concept that fecal retention can cause urinary symptoms, even in children with no underlying neurologic or anatomic abnormality. Our study is the first to our knowledge that shows that BMP alone can improve the VSS in children with FC. Additionally, we saw improvement in the BCS and CCCS scores as well. The BCS is a scoring measure used to assess

---

**Table 2** Univariate analysis of difference in score pre- and post-BMP among patients having undergone one BMP

| Measure          | Pre-BMP     | Post-BMP    | Mean diff | 95% CI       | $P$ value |
|------------------|-------------|-------------|-----------|--------------|-----------|
| VSS              | 2/37        | 14 (9, 20)  | 1/30      | 10 (6, 16)   | 3.6       |
|                  |             |             |           |              | 2.72      |
|                  |             |             |           |              | 4.48      |
|                  |             |             |           |              | $< 0.0001$ |
| BCS              | 11/78       | 30 (26, 42) | 5/68      | 20 (13, 28)  | 11.96     |
|                  |             |             |           |              | 9.41      |
|                  |             |             |           |              | 14.5      |
|                  |             |             |           |              | $< 0.0001$ |
| CCCS             | 2/25        | 12 (9, 16)  | 0/21      | 10 (8, 13)   | 1.9       |
|                  |             |             |           |              | 1.06      |
|                  |             |             |           |              | 2.73      |
|                  |             |             |           |              | $< 0.0001$ |

**Table 3** Univariate analysis of difference in score pre- and post-BMP among patients having undergone more than one BMP

| Measure          | Pre-BMP     | Post-BMP    | Mean diff | 95% CI       | $P$ value |
|------------------|-------------|-------------|-----------|--------------|-----------|
| VSS              | 1/33        | 11.5 (6, 20)| 1/29      | 10 (5, 16)   | 1.66      |
|                  |             |             |           |              | 0.23      |
|                  |             |             |           |              | 3.09      |
|                  |             |             |           |              | $0.0233$  |
| BCS              | 6/51        | 19.5 (12, 28)| 6/41      | 16.5 (11, 23)| 2.69      |
|                  |             |             |           |              | $-0.91$   |
|                  |             |             |           |              | 6.28      |
|                  |             |             |           |              | 0.14      |
|                  |             |             |           |              | $< .0001$ |
| CCCS             | 3/22        | 12 (8.5, 13)| 2/16      | 8.5 (5, 11)  | 2.93      |
|                  |             |             |           |              | 1.74      |
|                  |             |             |           |              | 4.11      |
|                  |             |             |           |              | $< .0001$ |

IQR interquartile range, CI confidence interval, BMP bowel management program, VSS vancouver symptom score for dysfunctional elimination syndrome, BCS baylor continence scale, CCCS cleveland clinic constipation score
The patients in this cohort had FC, not an anorectal malformation, but both populations have been known to have concomitant urinary dysfunction.

| Table 4  | Linear mixed effect regression modeling for each measure |
|----------|-------------------------------------------------------|
|          | VSS                                                   | BCS                                                   | CCCS                                                   |
|          | Estimate (95% CI)  | Standard Error  | P value | Estimate (95% CI)  | Standard Error  | P value | Estimate (95% CI)  | Standard Error  | P value |
| Intercept | 24.38 (20.04, 28.73) | 2.2 | <.0001 | 37.11 (30.56, 43.66) | 3.31 | <.0001 | 11.33 (8.68, 13.98) | 1.34 | <.0001 |
| Catheterized | Yes | 5.76 (−0.34, 11.85) | 0.064 | 9.51 (−4.48, 23.50) | 7.11 | 0.1819 | −0.06 (−5.73, 3.82) | 2.42 | 0.6921 |
|          | No | Reference | Reference | Reference |
| Number of BMPs | One | −1.41 (−3.87, 1.04) | 1.24 | 0.2571 | −7.22 (−10.87, −3.57) | 1.85 | 0.0001 | −1.30 (−2.77, 0.16) | 0.74 | 0.0811 |
|          | Two | −4.56 (−14.14, 5.02) | 4.85 | 0.3487 | −11.85 (−26.83, 3.13) | 7.6 | 0.1205 | −0.95 (−6.86, 4.96) | 2.99 | 0.7505 |
|          | Three | Reference | Reference | Reference |
| BMP regimen | Oral | 1.34 (−1.19, 3.88) | 1.29 | 0.2968 | 5.57 (1.36, 9.79) | 2.14 | 0.0098 | 0.95 (−0.66, 2.56) | 0.82 | 0.2474 |
|          | Oral & enema | −2.41 (−8.13, 3.30) | 2.9 | 0.406 | 4.42 (−4.21, 13.15) | 4.44 | 0.3199 | 0.01 (−3.35, 3.36) | 1.7 | 0.9976 |
|          | Oral & suppository | −0.44 (−12.15, 11.27) | 4.6 | 0.4405 | 13.20 (−9.08, 35.59) | 11.33 | 0.2448 | −1.78 (−10.03, 6.47) | 4.19 | 0.6719 |
|          | Enema & suppository | Reference | Reference | Reference |
| Time | Pre-BMP | Reference | Reference | Reference |
|          | Post-BMP | −3.20 (−4.09, −2.30) | 0.45 | <.0001 | −6.41 (−9.16, −3.67) | 1.39 | <.0001 | −3.08 (−4.04, −2.13) | 0.49 | <.0001 |
|          | Age at BMP | −0.61 (−0.89, −0.33) | 0.14 | <.0001 | 0.45 (−0.88, −0.02) | 0.22 | 0.0409 | 0.16 (−0.01, 0.33) | 0.08 | 0.0585 |

^BMP regimen and pre/post-BMP

All findings here were made with reference group being those on a medication regimen

P < 0.05 are in bold

CI confidence interval, BMP bowel management program, VSS vancouver symptom score for dysfunctional elimination syndrome, BCS baylor continence scale, CCCS cleveland clinic constipation score, Oral oral laxative/medication

social continence in children who have underwent repair of an anorectal malformation [17]. The patients in this cohort...
The CCCS, while validated for adults, is a scoring system that assesses the severity of symptoms of constipation [16]. Improvement in both of these scores, along with the VSS, supports the interrelatedness of constipation and urinary dysfunction.

It has been reported that nearly 50% of patients seen in pediatric urology clinics have issues with BBD [1, 19]. Bowel and bladder dysfunction can cause negative physical and psychosocial effects on children and their families [4]. Given the economic and psychosocial effects of BBD, it is important to identify adequate treatments that may prevent additional morbidity for patients suffering from it. Additionally, urologic testing commonly requires catheterization, radiation exposure, and sometimes sedation. The objective improvement in VSS seen in our study suggests that if a formal BMP is initiated as a first-line treatment for dysfunctional elimination, symptoms may improve enough to eliminate the need for such testing or any additional intervention aimed at bladder control and relief of urinary symptoms, such as medication.

This study does have several limitations. First, we were not able to accurately describe symptomatic improvement of urinary symptoms, so utilized various scoring metrics to study this population in a standardized manner. The VSS itself demonstrates 80% sensitivity and 91% specificity for dysfunctional elimination syndrome/BBD, meaning we may not be identifying all patients with BBD [7]. While the VSS focuses mainly on urinary symptoms, it is possible that an improvement in bowel symptoms may have led to an improved score. We did not assess the association of these scores with stool and urinary continence. The BCS and CCCS were not validated for our population of pediatric patients with FC and BBD. The median time at which the VSS was measured post-BMP was 92 days and, therefore, we are unable to describe the long-standing effects of a BMP on BBD, though long-standing effects may be

| Table 5 | Estimates of scores based on pre- and post-BMP regimen and comparison of means |
|---------|---------------------------------------------------------------------------------|
| **VSS** |                                                                                  |
| BMP Regimen | Pre-BMP | Post-BMP | Comparison of mean |
|           | Estimate (95% CI) | Estimate (95% CI) | Estimate (95% CI) | Standard Error | P value | Adjusted P value |
| Oral     | 17.40 (12.92, 21.89) | 14.72 (10.24, 19.19) | −2.69 (−4.43, −0.94) | 0.57 | <.0001 | **0.0001** |
| Enema    | 18.75 (14.25, 23.24) | 14.70 (10.32, 19.08) | −4.05 (−6.51, −1.58) | 0.81 | <.0001 | **<.0001** |
| Oral & enema | 14.99 (8.69, 21.28) | 11.28 (4.91, 17.64) | −3.71 (−10.70, 3.28) | 2.28 | 0.1055 | 0.7349 |
| Oral & suppository | 16.96 (4.56, 29.37) | 10.28 (0.16, 20.39) | −6.69 (−20.84, 7.47) | 4.63 | 0.1499 | 0.8353 |
| aEnema & suppository | − | − | − | − | − | − |
| **BCS** |                                                                                  |
| BMP regimen | Pre-BMP | Post-BMP | Comparison of mean |
|           | Estimate (95% CI) | Estimate (95% CI) | Estimate (95% CI) | Standard Error | P value | Adjusted P value |
| Oral     | 29.75 (21.05, 38.45) | 23.33 (14.63, 32.04) | −6.41 (−10.68, −2.15) | 1.39 | <.0001 | **0.0002** |
| Enema    | 35.32 (26.86, 43.79) | 20.65 (11.85, 29.45) | −14.67 (−20.43, −8.91) | 1.88 | <.0001 | **<.0001** |
| Oral & enema | 34.17 (23.16, 45.17) | 29.05 (16.90, 41.21) | −5.12 (−21.21, 10.98) | 5.26 | 0.332 | 0.978 |
| Oral & suppository | 42.95 (19.23, 66.66) | 23.42 (6.66, 40.18) | −19.52 (−54.14, 15.09) | 11.32 | 0.0861 | 0.6715 |
| aEnema & suppository | − | − | − | − | − | − |
| **CCCS** |                                                                                  |
| BMP regimen | Pre-BMP | Post-BMP | Comparison of mean |
|           | Estimate (95% CI) | Estimate (95% CI) | Estimate (95% CI) | Standard Error | P value | Adjusted P value |
| Oral     | 11.41 (8.24, 14.59) | 8.33 (5.15, 11.50) | −3.08 (−4.57, −1.60) | 0.49 | <.0001 | **<.0001** |
| Enema    | 12.36 (9.20, 15.51) | 10.96 (7.80, 14.13) | −1.40 (−3.33, 0.54) | 0.63 | 0.028 | 0.3499 |
| Oral & enema | 11.42 (7.32, 15.51) | 12.05 (7.50, 16.59) | 0.63 (−0.50, 6.29) | 1.85 | 0.734 | 1 |
| Oral & suppository | 9.63 (0.87, 18.40) | 12.73 (6.24, 19.23) | 3.10 (−8.82, 15.02) | 3.9 | 0.427 | 0.9932 |
| aEnema & suppository | − | − | − | − | − | − |

P < 0.05 are in bold

CI confidence interval, BMP bowel management program, Oral oral laxative/medication

Adjusted P value from Tukey adjustment

a95% CI = Tukey adjusted confidence interval

[6, 11, 15]. The CCCS, while validated for adults, is a scoring system that assesses the severity of symptoms of constipation [16]. Improvement in both of these scores, along with the VSS, supports the interrelatedness of constipation and urinary dysfunction.
difficult to interpret due to the normal waxing and waning disease course of FC and the relationship between stool habits with diet and bowel regimen compliance. Future studies should identify long-term results. Lastly, this is a single-institution study performed at a specialized, high-volume center, so results may not be generalizable.

We conclude that in children with functional constipation and concomitant bladder dysfunction, a bowel management program significantly improves urinary symptoms. Thus, in this patient population, a bowel management program should be undertaken prior to any other measures to control urinary symptoms.

**Author contributions** HA, RJW, MEF contributed to study conception and design. HA contributed to data collection. TB contributed to analysis and interpretation. MEK contributed to the drafting of the manuscript. All authors contributed to critical review and revision of the manuscript.

**Funding** None.

**Declarations**

**Competing interests** The authors declare no competing interests.

**Conflict of interest** None.

**References**

1. Jiang R, Kelly MS, Routh JC (2018) Assessment of pediatric bowel and bladder dysfunction: a critical appraisal of the literature. J Pediatr Urol 14(6):494–501
2. Aguiar LM, Franco I (2018) Bladder bowel dysfunction. Urol Clin North Am 45(4):633–640
3. Combs AJ, Van Batavia JP, Chan J, Glassberg KI (2013) Dysfunctional elimination syndromes—how closely linked are constipation and encopresis with specific lower urinary tract conditions? J Urol 190(3):1015–1020
4. Santos JD, Lopes RI, Koyle MA (2017) Bladder and bowel dysfunction in children: an update on the diagnosis and treatment of a common, but underdiagnosed pediatric problem. Can Urol Assoc J 11((1-2Suppl1)):S64–S72
5. Malykhina AP, Brodie KE, Wilcox DT (2017) Genitourinary and gastrointestinal co-morbidities in children: the role of neural circuits in regulation of visceral function. J Pediatr Urol 13(2):177–182
6. Yang S, Chua ME, Bauer S, Wright A, Brandström P, Hoebeke P et al (2018) Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the international children’s continence society. Pediatr Nephrol 33(12):2207–2219
7. Afshar K, Mirbagheri A, Scott H, Macneil AE (2009) Development of a symptom score for dysfunctional elimination syndrome. J Urol 182(4S):1939–1944
8. Hoen LA, Korfage IJ, Verhallen JT, van Ledden-Klok MJ, van den Hoek J, Blok BF et al (2016) Vancouver symptom score for dysfunctional elimination syndrome: reliability and validity of the dutch version. J Urol 196(2):536–541
9. Assis GM, Silva CPCd, Martins G (2019) Urotherapy in the treatment of children and adolescents with bladder and bowel dysfunction: a systematic review. J de Pediatr 95(6):628–641
10. Koff SA, Wagner TT, Jayanthi VR (1998) The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. J Urol 160(3 Pt 2):1019–1022
11. Loening-Baucke V (1997) Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation. Pediatrics 100(2 Pt 1):228–232
12. Bischoff A, Levitt MA, Peña A (2009) Bowel management for the treatment of pediatric fecal incontinence. Pediatr Surg Int 25(12):1027–1042
13. Kilpatrick JA, Zobell S, Leeflang EJ, Cao D, Mammen L, Rollins MD (2020) Intermediate and long-term outcomes of a bowel management program for children with severe constipation or fecal incontinence. J Pediatr Surg 55(3):545–548
14. Reck-Burneo CA, Vilanova-Sanchez A, Gasior AC, Dingemans AJM, Lane VA, Dyckes R et al (2018) A structured bowel management program for patients with severe functional constipation can help decrease emergency department visits, hospital admissions, and healthcare costs. J Pediatr Surg 53(9):1737–1741
15. Wood RJ, Vilanova-Sanchez A, El-Gohary Y, Ahmad H, Halleran DR, Reck-Burneo CA et al (2021) One-year impact of a bowel management program in treating fecal incontinence in patients with anorectal malformations. J Pediatr Surg. https://doi.org/10.1016/j. jpedsurg.2021.04.029
16. Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD (1996) A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 39(6):681–685
17. Brandt ML, Daigneau C, Graviss EA, Naik-Mathuria B, Fitch ME, Washburn KK (2007) Validation of the Baylor Continence Scale in children with anorectal malformations. J Pediatr Surg 42(6):1015–1021 (discussion 21)
18. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M (2016) Functional disorders: children and adolescents. Gastroenterology 150(6):1456–1468
19. Burgers R, de Jong TP, Visser M, Di Lorenzo C, Dijkgraaf MG, Benninga MA (2013) Functional defecation disorders in children with lower urinary tract symptoms. J Urol 189(5):1866–1891

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.